申请人:Nippon Zoki Pharmaceutical Co., Ltd.
公开号:EP2298313A1
公开(公告)日:2011-03-23
Disclosed is a novel pharmaceutical composition for external application for increasing the permeation of prochlorperazine or a pharmaceutically acceptable salt thereof through the skin to allow prochlorperazine or the pharmaceutically acceptable salt thereof to exhibit its excellent pharmacological activity. Specifically disclosed is a novel pharmaceutical composition for external application which contains prochlorperazine or a pharmaceutically acceptable salt thereof as an active ingredient and further contains menthol. The composition contains, as an active ingredient, prochlorperazine which has been widely used clinically as the first-line drug of a therapeutic agent for nausea or vomiting before or after a surgery or the like, and is extremely highly useful as a transdermally absorbable antiemetic agent that has excellent efficacy and car be used safely over a long period.
本发明公开了一种新型外用药物组合物,该组合物可增加丙氯苯嗪或其药学上可接受的盐在皮肤中的渗透性,从而使丙氯苯嗪或其药学上可接受的盐发挥其卓越的药理活性。具体公开了一种新型外用药物组合物,它含有作为活性成分的丙氯丙嗪或其药学上可接受的盐,并进一步含有薄荷醇。该组合物含有作为活性成分的丙氯苯嗪,丙氯苯嗪在临床上被广泛用作治疗手术前后恶心或呕吐等症状的一线药物,作为一种可透皮吸收的止吐药,丙氯苯嗪具有极高的效用,而且可以长期安全使用。